DiaMedica Therapeutics In... (DMAC)
NASDAQ: DMAC
· Real-Time Price · USD
3.56
0.05 (1.42%)
At close: Jun 17, 2025, 10:22 AM
1.42% (1D)
| Bid | 3.54 |
| Market Cap | 152.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27M |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -5.57 |
| Forward PE | -4.58 |
| Analyst | Buy |
| Ask | 3.58 |
| Volume | 23,265 |
| Avg. Volume (20D) | 101,720 |
| Open | 3.62 |
| Previous Close | 3.51 |
| Day's Range | 3.52 - 3.63 |
| 52-Week Range | 2.14 - 6.82 |
| Beta | 1.20 |
About DMAC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DMAC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DMAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-13.02%
DiaMedica Therapeutics shares are trading lower fo...
Unlock content with
Pro Subscription
1 month ago · seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financi...
3 months ago · seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conf...
